Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
Public ClinicalTrials.gov record NCT02963922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT02963922
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 396 participants
Conditions and interventions
Conditions
Interventions
- Liraglutide 3.0 mg Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 5, 2017
- Primary completion
- Sep 9, 2018
- Completion
- Sep 24, 2018
- Last update posted
- Mar 29, 2020
2017 – 2018
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Birmingham | Alabama | 35294 | — |
| Novo Nordisk Investigational Site | Concord | California | 94520 | — |
| Novo Nordisk Investigational Site | Fresno | California | 93720 | — |
| Novo Nordisk Investigational Site | Jacksonville | Florida | 32205 | — |
| Novo Nordisk Investigational Site | Plantation | Florida | 33324 | — |
| Novo Nordisk Investigational Site | Roswell | Georgia | 30076 | — |
| Novo Nordisk Investigational Site | Honolulu | Hawaii | 96814 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60607 | — |
| Novo Nordisk Investigational Site | Louisville | Kentucky | 40213 | — |
| Novo Nordisk Investigational Site | North Dartmouth | Massachusetts | 02747 | — |
| Novo Nordisk Investigational Site | Minneapolis | Minnesota | 55416 | — |
| Novo Nordisk Investigational Site | Butte | Montana | 59701 | — |
| Novo Nordisk Investigational Site | Albany | New York | 12206 | — |
| Novo Nordisk Investigational Site | Wilmington | North Carolina | 28401 | — |
| Novo Nordisk Investigational Site | Austin | Texas | 78731 | — |
| Novo Nordisk Investigational Site | Austin | Texas | 78749 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75230 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75231 | — |
| Novo Nordisk Investigational Site | Winchester | Virginia | 22601-3834 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02963922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 29, 2020 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02963922 live on ClinicalTrials.gov.